A Novel Non-Invasive Approach Based on Serum Ceruloplasmin for Identifying Non-Alcoholic Steatohepatitis Patients in the Non-Diabetic Population

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2022 Jul 7

PMID 35795637

Authors

Qingling Wang

Da Zhou

Mingjie Wang

Mingyu Zhu

Peizhan Chen

Hu Li

Meng Lu

Xinxin Zhang

Xizhong Shen

Taotao Liu

Li Chen

Affiliations

Soon will be listed here.

Abstract

Background And Aim: Few non-invasive models were established to identify patients with non-alcoholic steatohepatitis (NASH). Liver biopsy remains the gold standard in the clinic. Decreased serum ceruloplasmin (CP) is reported in patients with non-alcoholic fatty liver disease (NAFLD). We aimed to develop a non-invasive model incorporating CP for identifying NASH from NAFLD without type 2 diabetes mellitus (T2DM).

Methods: A total of 138 biopsy-proven patients with NAFLD without T2DM were enrolled. The CP ratio was calculated for standardization as the CP value divided by the lower limit of normal. The clinical, anthropometric, biochemical, and histological parameters were compared between the low and high CP ratio groups divided by the median value. Multivariate logistic regression analysis was performed to develop a model for identifying NASH in patients with NAFLD.

Results: The medians of the high ( = 69) and low ( = 69) CP ratio groups were 1.43 (1.28-1.61) and 1.03 (0.94-1.12), respectively. A comparison of the two groups showed that the severity of steatosis, hepatocellular ballooning, inflammation activity, fibrosis, and liver iron deposition decreased along with the CP ratio ( < 0.05). The median CP ratio of patients with NASH was significantly lower than those with NAFL [1.15 (1.01-1.41) . 1.33 (1.24-1.54), = 0.001]. A novel model which consists of the CP ratio, BMI, and aspartate aminotransferase (AST) was developed. The AUCs of the model in discriminating NASH from NAFLD was 0.796 (0.694-0.899) and 0.849 (0.713-0.984) in the training and validation groups, and 0.836 (0.659-1.000), 0.833 (0.705-0.962), and 0.821 (0.612-1.000) in patients with normal serum alanine aminotransferase, AST, and both levels, respectively.

Conclusions: Decreased CP ratio is associated with more severe histological activity, a diagnosis of NASH, and hepatic iron deposition among patients with NAFLD without T2DM. The CP ratio model could be served as a non-invasive approach to identifying patients with NASH, which might reduce the need for liver biopsy.

Citing Articles

Exploring the Role of Metabolic Hyperferritinaemia (MHF) in Steatotic Liver Disease (SLD) and Hepatocellular Carcinoma (HCC).

Anastasopoulos N, Barbouti A, Goussia A, Christodoulou D, Glantzounis G Cancers (Basel). 2025; 17(5).

PMID: 40075688 PMC: 11899477. DOI: 10.3390/cancers17050842.

Lipid dysmetabolism in ceruloplasmin-deficient mice revealed both in vivo and ex vivo by MRI, MRS and NMR analyses.

Mannella V, Chaabane L, Canu T, Zanardi A, Raia S, Conti A FEBS Open Bio. 2023; 14(2):258-275.

PMID: 37986139 PMC: 10839333. DOI: 10.1002/2211-5463.13740.

References

Aigner E, Strasser M, Haufe H, Sonnweber T, Hohla F, Stadlmayr A . A role for low hepatic copper concentrations in nonalcoholic Fatty liver disease. Am J Gastroenterol. 2010; 105(9):1978-85. DOI: 10.1038/ajg.2010.170. View

Nobili V, Siotto M, Bedogni G, Rava L, Pietrobattista A, Panera N . Levels of serum ceruloplasmin associate with pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2012; 56(4):370-5. DOI: 10.1097/MPG.0b013e31827aced4. View

Heffern M, Park H, Au-Yeung H, Van de Bittner G, Ackerman C, Stahl A . In vivo bioluminescence imaging reveals copper deficiency in a murine model of nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A. 2016; 113(50):14219-14224. PMC: 5167165. DOI: 10.1073/pnas.1613628113. View

Gitlin J . Transcriptional regulation of ceruloplasmin gene expression during inflammation. J Biol Chem. 1988; 263(13):6281-7. View

Corradini E, Buzzetti E, Dongiovanni P, Scarlini S, Caleffi A, Pelusi S . Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. J Hepatol. 2021; 75(3):506-513. DOI: 10.1016/j.jhep.2021.03.014. View

Aigner E, Theurl I, Haufe H, Seifert M, Hohla F, Scharinger L . Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. Gastroenterology. 2008; 135(2):680-8. DOI: 10.1053/j.gastro.2008.04.007. View

Bedossa P, Poitou C, Veyrie N, Bouillot J, Basdevant A, Paradis V . Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012; 56(5):1751-9. DOI: 10.1002/hep.25889. View

France M, Kwok S, Soran H, Williams S, Ho J, Adam S . Liver Fat Measured by MR Spectroscopy: Estimate of Imprecision and Relationship with Serum Glycerol, Caeruloplasmin and Non-Esterified Fatty Acids. Int J Mol Sci. 2016; 17(7). PMC: 4964465. DOI: 10.3390/ijms17071089. View

Singh S, Allen A, Wang Z, Prokop L, Murad M, Loomba R . Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2014; 13(4):643-54.e1-9. PMC: 4208976. DOI: 10.1016/j.cgh.2014.04.014. View

10.

Verma S, Jensen D, Hart J, Mohanty S . Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013; 33(9):1398-405. DOI: 10.1111/liv.12226. View

11.

Gitlin J, Schroeder J, Cousins R . Mechanisms of caeruloplasmin biosynthesis in normal and copper-deficient rats. Biochem J. 1992; 282 ( Pt 3):835-9. PMC: 1130863. DOI: 10.1042/bj2820835. View

12.

Billeter A, Wloka S, Behnisch R, Albrecht T, Roessler S, Goeppert B . Development and Validation of a Novel Scoring System for Noninvasive Nonalcoholic Steatohepatitis Detection in Bariatric Patients. Obes Facts. 2021; 14(5):490-500. PMC: 8546458. DOI: 10.1159/000517383. View

13.

. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2019; 43(Suppl 1):S14-S31. DOI: 10.2337/dc20-S002. View

14.

De Domenico I, Ward D, Bonaccorsi di Patti M, Jeong S, David S, Musci G . Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J. 2007; 26(12):2823-31. PMC: 1894773. DOI: 10.1038/sj.emboj.7601735. View

15.

Nalbantoglu I, Brunt E . Role of liver biopsy in nonalcoholic fatty liver disease. World J Gastroenterol. 2014; 20(27):9026-37. PMC: 4112884. DOI: 10.3748/wjg.v20.i27.9026. View

16.

Shang Y, Luo M, Yao F, Wang S, Yuan Z, Yang Y . Ceruloplasmin suppresses ferroptosis by regulating iron homeostasis in hepatocellular carcinoma cells. Cell Signal. 2020; 72:109633. DOI: 10.1016/j.cellsig.2020.109633. View

17.

Kang N, Zhang J, Lin M, Chen X, Huang Z, Zhu Y . Serum ceruloplasmin can predict liver fibrosis in hepatitis B virus-infected patients. World J Gastroenterol. 2020; 26(27):3952-3962. PMC: 7385565. DOI: 10.3748/wjg.v26.i27.3952. View

18.

Fracanzani A, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E . Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008; 48(3):792-8. DOI: 10.1002/hep.22429. View

19.

Sheka A, Adeyi O, Thompson J, Hameed B, Crawford P, Ikramuddin S . Nonalcoholic Steatohepatitis: A Review. JAMA. 2020; 323(12):1175-1183. DOI: 10.1001/jama.2020.2298. View

20.

Anty R, Iannelli A, Patouraux S, Bonnafous S, Lavallard V, Senni-Buratti M . A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther. 2010; 32(11-12):1315-22. DOI: 10.1111/j.1365-2036.2010.04480.x. View